IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
Chromium picolinate supplementation for overweight or obese adults
Tian, Hongliang1; Guo, Xiaohu2; Wang, Xiyu3; He, Zhiyun2; Sun, Rao3; Ge, Sai4; Zhang, Zongjiu3
刊名COCHRANE DATABASE OF SYSTEMATIC REVIEWS
2013
DOI10.1002/14651858.CD010063.pub2
11
收录类别SCI
文章类型Review
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
研究领域[WOS]General & Internal Medicine
关键词[WOS]RANDOMIZED CONTROLLED-TRIALS ; TYPE-2 DIABETES-MELLITUS ; RESTING METABOLIC-RATE ; BODY-COMPOSITION ; GLUCOSE-METABOLISM ; OLDER MEN ; WEIGHT ; WOMEN ; METAANALYSIS ; COMBINATION
英文摘要

Background

Obesity is a global public health threat. Chromium picolinate (CrP) is advocated in the medical literature for the reduction of body weight, and preparations are sold as slimming aids in the USA and Europe, and on the Internet.

Objectives

To assess the effects of CrP supplementation in overweight or obese people.

Search methods

We searched The Cochrane Library, MEDLINE, EMBASE, ISI Web of Knowledge, the Chinese Biomedical Literature Database, the China Journal Fulltext Database and the Chinese Scientific Journals Fulltext Database (all databases to December 2012), as well as other sources (including databases of ongoing trials, clinical trials registers and reference lists).

Selection criteria

We included trials if they were randomised controlled trials (RCT) of CrP supplementation in people who were overweight or obese. We excluded studies including children, pregnant women or individuals with serious medical conditions.

Data collection and analysis

Two authors independently screened titles and abstracts for relevance. Screening for inclusion, data extraction and ′Risk of bias′ assessment were carried out by one author and checked by a second. We assessed the risk of bias by evaluating the domains selection, performance, attrition, detection and reporting bias. We performed a meta-analysis of included trials using Review Manager 5.

Main results

We evaluated nine RCTs involving a total of 622 participants. The RCTs were conducted in the community setting, with interventions mainly delivered by health professionals, and had a short- to medium-term follow up (up to 24 weeks). Three RCTs compared CrP plus resistance or weight training with placebo plus resistance or weight training, the other RCTs compared CrP alone versus placebo.

We focused this review on investigating which dose of CrP would prove most effective versus placebo and therefore assessed the results according to CrP dose. However, in order to find out if CrP works in general, we also analysed the effect of all pooled CrP doses versus placebo on body weight only.

Across all CrP doses investigated (200 mu g, 400 mu g, 500 mu g, 1000 mu g) we noted an effect on body weight in favour of CrP of debatable clinical relevance after 12 to 16 weeks of treatment: mean difference (MD) -1.1 kg (95% CI -1.7 to -0.4); P = 0.001; 392 participants; 6 trials; low-quality evidence (GRADE)). No firm evidence and no dose gradient could be established when comparing different doses of CrP with placebo for various weight loss measures (body weight, body mass index, percentage body fat composition, change in waist circumference).

Only three studies provided information on adverse events (low-quality evidence (GRADE)). There were two serious adverse events and study dropouts in participants taking 1000 mu g CrP, and one serious adverse event in an individual taking 400 mu g CrP. Two participants receiving placebo discontinued due to adverse events; one event was reported as serious. No study reported on all-cause mortality, morbidity, health-related quality of life or socioeconomic effects. Authors′ conclusions We found no current, reliable evidence to inform firm decisions about the efficacy and safety of CrP supplements in overweight or obese adults.

语种英语
WOS记录号WOS:000327587700027
引用统计
被引频次:4[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/66909
专题北京大学临床肿瘤学院
作者单位1.Lanzhou Univ, Sch Clin Med 2, Lanzhou 730000, Peoples R China
2.Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Sch Clin Med 1, Lanzhou 730000, Peoples R China
3.Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Lanzhou 730000, Peoples R China
4.Beijing Univ, Beijing Canc Hosp, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Tian, Hongliang,Guo, Xiaohu,Wang, Xiyu,et al. Chromium picolinate supplementation for overweight or obese adults[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS,2013(11).
APA Tian, Hongliang.,Guo, Xiaohu.,Wang, Xiyu.,He, Zhiyun.,Sun, Rao.,...&Zhang, Zongjiu.(2013).Chromium picolinate supplementation for overweight or obese adults.COCHRANE DATABASE OF SYSTEMATIC REVIEWS(11).
MLA Tian, Hongliang,et al."Chromium picolinate supplementation for overweight or obese adults".COCHRANE DATABASE OF SYSTEMATIC REVIEWS .11(2013).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Tian, Hongliang]的文章
[Guo, Xiaohu]的文章
[Wang, Xiyu]的文章
百度学术
百度学术中相似的文章
[Tian, Hongliang]的文章
[Guo, Xiaohu]的文章
[Wang, Xiyu]的文章
必应学术
必应学术中相似的文章
[Tian, Hongliang]的文章
[Guo, Xiaohu]的文章
[Wang, Xiyu]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。